The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communicat
- PDF / 982,868 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 142 Views
ORIGINAL RESEARCH ARTICLE
The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir‑Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women Eva Agnes Odongpiny Laker1 · Arnold Arinaitwe1 · Noela Owarwo1 · Annet Onzia1 · Benson Nasasira1 · Abdullah Wailagala1 · Ivan Kalule1 · Godwin Anguzu1 · Agnes Kiragga1 · Kay Seden2 · Isaac Lwanga1 · Barbara Castelnuovo1 · Rachel Musomba1 · Mohammed Lamorde1
© Springer Nature Switzerland AG 2020
Abstract Introduction and Objective In May 2018, the World Health Organization and other regulatory authorities released a safety alert for dolutegravir related to a risk of neural tube defects among women exposed to dolutegravir at the time of conception. Models of how drug safety information can be shared effectively in the shortest time are necessary to prevent interruptions of public health programs. We sought to describe an implementation process to inform and support women already on dolutegravir-based regimens at the time of conception to make informed choices following the safety alert of a potential teratogenicity risk. We describe the choices made by women, as well as determine the factors associated with women’s choices to switch off dolutegravir. Methods A clinic response plan was developed in the first week following the alert and clinic staff were trained on safety guidance. All women aged
Data Loading...
